Stereotaxis, Inc. reported a 20% increase in revenue for the fiscal year ending December 31, 2025, reaching $32.4 million compared to $26.9 million in 2024. This growth was driven by a rise in system sales, which increased by approximately 18% to $10.2 million, and a 21% increase in revenue from disposable interventional devices, service, and accessories, totaling $22.2 million. Despite this revenue growth, the company reported a net loss of $21.6 million, slightly improved from a loss of $24.0 million in the previous year. The increase in costs of revenue, which rose by 24% to $15.3 million, contributed to the operating loss of $22.1 million, although gross margins remained relatively stable at 53% for 2025.
The company experienced significant operational changes, including the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, which added a portfolio of diagnostic catheters to Stereotaxis' offerings. This acquisition is expected to enhance Stereotaxis' innovation capabilities in developing interventional devices. The integration of APT is ongoing, and the company anticipates realizing synergies and operational efficiencies as it combines resources. As of December 31, 2025, Stereotaxis had a system backlog of approximately $9.1 million, with expectations to recognize about 78% of this as revenue in 2026.
In terms of operational metrics, Stereotaxis reported that over 150,000 arrhythmia patients have been treated globally using its robotic technology, with clinical use documented in over 500 publications. The company has also made strides in regulatory approvals, achieving CE Mark for the GenesisX RMN System and the Synchrony Solution, and FDA 510(k) clearance for the MAGiC catheter, which is expected to enhance its market position. The company’s employee headcount stood at 131 as of December 31, 2025, with a focus on maintaining a skilled workforce to support its growth initiatives.
Looking ahead, Stereotaxis faces challenges related to macroeconomic conditions, including supply chain disruptions and inflationary pressures, which could impact its ability to meet customer demand and manage costs effectively. The company is also navigating a lengthy sales cycle for its robotic magnetic navigation systems, which may lead to fluctuations in revenue recognition. Despite these challenges, Stereotaxis remains optimistic about its growth trajectory, driven by ongoing product development and strategic partnerships in the interventional market. The company plans to continue leveraging its innovative technologies to expand its market share and improve patient outcomes in the evolving healthcare landscape.
About Stereotaxis, Inc.
Stereotaxis designs and markets robotic systems for minimally invasive interventional procedures, primarily in electrophysiology and cardiology. Its core products include magnetic navigation systems, integrated information solutions, and compatible disposable devices. The company enhances procedural precision, safety, and efficiency, enabling complex treatments with broader physician access. Operating globally, it leverages strategic partnerships, regulatory expertise, and innovative R&D to advance robotic medical technology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.